ClinicalTrials.gg
Not yet recruitingNCT07854847Updated Oct 2, 2026

Study Interchangeability Hep-B Vaccine Administered at Birth Dose

A Phase 3 interventional study of In-house Hepatitis B Vaccine and Registered Hepatitis B Vaccine in Vaccination Adverse Event and Immunogenicity, Vaccine, sponsored by PT Bio Farma. Not yet recruiting. Open to participants aged 0 Days to 3 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by PT Bio Farma · Phase 3, Interventional, and Prevention

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
0 Days to 3 Days
Sex
All
01

Study summary

This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.

Read the detailed description

This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.

Approximately 270 newborns will be enrolled in this trial, divided into 2 arms, with the ratio 1:1. The subject will receive one dose of In-House Recombinant Hepatitis B at birth or registered monovalent Hepatitis B as a control then followed by registered DTwP-HepB-IPVHib (HEXASIIL) vaccine

02

Conditions studied

  • Vaccination Adverse Event
  • Immunogenicity, Vaccine

Browse trials for

Keywords

  • Vaccine
  • Hepatitis B
03

In context

Hepatitis B

1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

This study's planned enrollment of 270 is above the median of 145 across 757 interventional studies indexed under Hepatitis B.

Browse Hepatitis B studies →

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 3 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, full term, newborn infants.
  2. Infant born between 37-42 weeks of pregnancy.
  3. Infant weigh between 2500 - 4000 gram at birth.
  4. Father, mother or legally acceptable representative properly informed about the study and having signed the form.
  5. Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Infants concomitantly enrolled or scheduled to be enrolled in another trial.
  2. Infants evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature ≥ 37.5°C on Day 0).
  3. Infants suspected of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection, based on anamnesis.
  4. Infants received or plans to receive any treatment likely to alter the immune response intravenously (immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks)).
  5. Infants received other vaccinations with the exception of BCG, poliomyelitis, rotavirus, and PCV.
  6. Infants with HbsAg and positive (from cord blood)
  7. Mother suspected of immunodeficiency disease based on anamnesis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Hep B vaccine in-house

    0,5 ml of In-house Recombinant Hepatitis B (Bio Farma) vaccine injected at birth

    Biological: In-house Hepatitis B Vaccine

  • Active comparator
    Registered Hep B vaccine

    0,5 ml of Regstered Hepatitis B (Bio Farma) vaccine injected at birth

    Biological: Registered Hepatitis B Vaccine

Interventions

  • BiologicalIn-house Hepatitis B Vaccine

    0,5 ml In-House Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh

  • BiologicalRegistered Hepatitis B Vaccine

    0,5 ml Registered Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh

06

What researchers measure

Primary outcomes

  1. Protectivity of primary series In-House Recombinant Hepatitis B vaccine

    Percentage of subjects with anti HBsAg \> 10mIU/ml after the completion of the primary series of recombinant hepatitis B and Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine for each group

    Time frame: 28 days after administration of third dose of DTwP-HepB-IPV-Hib (HEXASIIL) vaccine

Secondary outcomes

  1. Immunogenicity of birth dose In-House Recombinant Hepatitis B vaccine

    GMT and percentage of infants with increasing antibody titer ≥ 4 times and/ or percentage of infants with transition of seronegative to seropositive after birth dose Hep B vaccine

    Time frame: 28 days after administration of Hep B birth dose vaccine

  2. Immunogenicity of In-House recombinant Hepatitis B vaccine after the completion of Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine

    GMT and percentage of infants with increasing antibody titer ≥ 4 times and/ or percentage of infants with transition of seronegative to seropositive after completion of Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine

    Time frame: 28 days after the third dose of DTwP-HepB-IPV-Hib (HEXASIIL) vaccine

  3. Safety of In-House Recombinant Hepatitis B vaccine

    Percentage of subjects with solicited and unsolicited adverse events after each dose

    Time frame: 30 minutes, 7 days, 28 days after each dose

  4. Serious Adverse Events

    Percentage of infants with at least one serious adverse events

    Time frame: 28 days after third dose of Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

Of 42 industry-sponsored phase 3 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Oct 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jul 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854847
Lead sponsor
PT Bio Farma
Collaborators
Universitas Padjadjaran
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Rini Mulia Sari, MD
Contact
rini.mulia@biofarma.co.id
+622033755 ext. 14102
Mita Puspita, MD
Contact
mita.puspita@biofarma.co.id
+622033755 ext. 5045
Rodman Tarigan Girsang, MD
principal investigator · Faculty of Medicine, Padjadjaran University, Bandung

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion